The increasing prevalence of cancer in pets and the rising awareness about pet health issues are driving the growth of the pet cancer therapeutics market. Additionally, advancements in veterinary medicine and technology are leading to the development of more effective treatments for pet cancer.
Industry
Report Coverage | Details |
---|---|
Segments Covered | Therapy, Applications |
Regions Covered | • North America (United States, Canada, Mexico) • Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe) • Asia Pacific (China, Japan, South Korea, Singapore, India, Australia, Rest of APAC) • Latin America (Argentina, Brazil, Rest of South America) • Middle East & Africa (GCC, South Africa, Rest of MEA) |
Company Profiled | AB Science, Anivive Lifesciences, Elanco Animal Health, ELIAS Animal Health, Merial, NovaVive, Qbiotics, Zoetis |
The high treatment costs and limited availability of pet cancer therapeutics are major restraints in the market. The high cost of cancer treatment for pets can be a barrier for many pet owners, limiting the adoption of these therapies. Additionally, the limited availability of specialized pet cancer treatments in certain regions can also hinder market growth.